• CD28 targeting
  • How it works

CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B‑cell lymphoma xenograft model. Xavier Chauchet, Laura Cons, et al.

Xavier Chauchet, Laura Cons, et al.

AACR-2022 NI-3201 CD28 bispecific antibody platform

AACR Annual Meeting 2022 - Sara Majocchi -

AACR-2022 NI-2601 & NI-2901 CD47xPD-L1 bispecific antibodies

AACR Annual Meeting 2022 - Xavier Chauchet -

Upcoming conferences - March 2022

We are looking forward to meeting you in person at the follwing events.

SITC 2021, NI-2601 & NI-2901 bispecific antibody programs

36th Annual Meeting & Pre-Conference Programs (SITC)

TM & © Novimmune SA. All rights reserved.
webdesign byhosted climate friendly

Targeting CD47 will be discussed at ITOC 2026

Written by Remi Jeandenand on . Posted in News

Read more

LinkedIn